Holen Sie sich die Stockscreener-App
261.91
0.45%
1.17
Handel nachbörslich:
261.00
-0.91
-0.35%
Schlusskurs vom Vortag:
$260.74
Offen:
$262.42
24-Stunden-Volumen:
3.40M
Relative Volume:
2.28
Marktkapitalisierung:
$37.51B
Einnahmen:
$2.50B
Nettoeinkommen (Verlust:
$-226.32M
KGV:
-159.58
EPS:
-1.6412
Netto-Cashflow:
$71.51M
1W Leistung:
+13.18%
1M Leistung:
+30.36%
6M Leistung:
+12.05%
1J Leistung:
+55.74%
1-Tages-Spanne:
$257.07
$270.43
1-Wochen-Bereich:
$219.50
$271.47
52-Wochen-Spanne:
$131.81
$271.47
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | William Blair | Outperform |
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera director Herm Rosenman sells $4.13m in common stock - Investing.com UK
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com Nigeria
Natera(NTRA.US) Officer Sells US$8.46 Million in Common Stock - Moomoo
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Natera legal officer Daniel Rabinowitz sells $8.45m in shares - Investing.com
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com India
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com India
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com South Africa
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
What's Driving Natera's Recent Stock Action - Kavout | AI
Natera, Inc. Actuals & Estimates (NASDAQ:NTRA) - TradingView
Banu Saritas-Yildirim: Signatera is Approved in Japan by FDA - Oncodaily
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
NTRA Forecast — Price Target — Prediction for 2027 - TradingView
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - The Globe and Mail
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com Australia
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar? - Yahoo Finance Singapore
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial - TradingView
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire
Barclays Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $260 - Moomoo
Biotech Medical Test Leader Hits Record High, Joins 15 Others New To Best Stock Lists - Investor's Business Daily
Form 144 NATERA For: 24 June By Investing.com - Investing.com Nigeria
[144] Natera, Inc. SEC Filing - Stock Titan
This Medtech Stock Just Flashed A Buy Signal; Here's Why - Investor's Business Daily
Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets - StocksToTrade
Why Natera (NTRA) Stock Is Up Today - Yahoo Finance
Natera Inc stock hits all-time high at 256.57 USD By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Raised to $275 - GuruFocus
Natera Stock Jumps As NCCN Endorses Signatera MRD Test - timothysykes.com
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Benzinga
Natera (NTRA) Achieves First MRD Test Approval in Japan - GuruFocus
Natera Surges As Signatera Wins Big Cancer Milestones - TipRanks
Natera (NTRA) Is Up 6.7% After First PMDA-Approved MRD Test in JapanWhat's Changed - simplywall.st
Natera Inc stock hits all-time high at 256.57 USD - Investing.com
Natera Stock Jumps as Investors Focus on Fresh Clinical Data and Strong Growth Outlook - Moomoo
Natera stock jumps as investors focus on fresh clinical data and strong growth outlook - Quiver Quantitative
Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera - Blockonomi
Natera, Inc. (NTRA) Stock: Surges 7% as Signatera Wins Japan Approval - CoinCentral
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $249 to $285 - Moomoo
ETFs Investing in Natera, Inc. Stocks - TradingView
Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer - Yahoo Finance
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROSENMAN HERM | Director |
Jun 24 '26 |
Sale |
250.00 |
16,530 |
4,132,500 |
4,250 |
0.66%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):